Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Financial Results

Every financial results filing by a US-listed company that our alert engine sent, newest first.

8:16 AM ET 10-Q
Financial Results Theriva Biologics, Inc. TOVX

Theriva Biologics Q3 2026 Results: Net Loss of $1.47M, Loss Narrows

Theriva Biologics reported a net loss of $6.7 million for the nine months ended September 30, 2026, a significant improvement from the $21.7 million loss in the prior year period. The company generated $0.3 million in license revenue and substantially reduced operating expenses, while maintaining a cash balance of $8.5 million as of the end of the quarter.

Key figure
Net loss $1.47M
8:16 AM ET 10-Q
Financial Results Avalyn Pharma Inc. AVLN

Avalyn Pharma Q3 2026 Results: Net Loss of $29.7M, Loss Widens

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing inhaled antifibrotic therapies for pulmonary fibrosis, specifically lead candidates AP01 and AP02. As of November 10, 2026, the company reported 44,521,494 shares of voting common stock outstanding and continues to incur significant operating losses to fund its research and development programs.

Key figure
Net loss $29.7M
8:16 AM ET 10-Q
Financial Results SeaStar Medical Holding Corp ICU

SeaStar Medical Holding Q3 2026 Results: Net Loss of $4.53M, Loss Widens

SeaStar Medical reported a net loss of $11.8 million for the nine months ended September 30, 2026, compared to $9.2 million in the prior year period, driven by increased research and development expenses. Total revenue grew to $1.7 million from $0.8 million year-over-year, while cash reserves decreased significantly to $4.0 million from $12.0 million at the start of the year.

Key figure
Net loss $4.53M
8:15 AM ET 8-K
Financial Results SES AI Corp SES

SES AI Financial Results

SES AI Corp reported its Q3 2026 financial results, highlighting a 31% sequential revenue increase to $6.6 million and a narrowing GAAP net loss of $13.4 million. The company successfully ramped its Chungju production line to 1 million cells per year and introduced its 'Flywheel' strategy focusing on drones, energy storage, and material discovery.

Term
3 years
8:14 AM ET 8-K
Financial Results Suburban Propane Partners LP SPH

Suburban Propane Partners Financial Results

Suburban Propane Partners reported fiscal year 2026 net income of $109.0 million and Adjusted EBITDA of $284.0 million, a 2.2% increase over the prior year. The company highlighted strong heat-related demand in its propane segment and a 13% increase in average daily renewable natural gas (RNG) injections following facility upgrades and new capacity in New York.

Term
FY2026

“Fiscal 2026 was another strong year for Suburban Propane with solid results in our propane operations, the completion of capital projects to increase the scale of our renewable natural gas (“RNG”) business, and continued debt reduction to further strengthen our financial position.”

Michael A. Stivala, President and Chief Executive Officer

“With these investments in place, we enter fiscal 2027 with a larger, more reliable RNG platform, opportunities to increase production through capacity optimization and higher feedstock intake, and the ability to enhance our earnings profile from the recognition of additional PTCs.”

Michael A. Stivala, President and Chief Executive Officer
8:14 AM ET 10-Q
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Q3 2026 Results: Net Loss of $51.2M, Loss Widens

MeiraGTx reported a significant increase in total revenue to $326.5 million for the nine months ended September 30, 2026, primarily driven by license and service revenue from related parties. This resulted in a net income of $63.1 million for the period, compared to a net loss of $129.3 million in the prior year, despite a net loss in the third quarter of 2026.

Key figure
Net loss $51.2M
8:13 AM ET 8-K
Financial Results Dixie Group Inc DXYN

Dixie Group Financial Results

The Dixie Group reported its third consecutive profitable quarter, with net sales increasing 4.6% to $65.2 million and net income of $577,000 compared to a significant loss in the prior year. The company attributed the improvement to cost reductions and operating efficiencies despite industry headwinds from high interest rates and inflation.

Term
Q3 2026

“We are pleased to report our third consecutive profitable quarter of 2026. Net sales increased 4.6% over the third quarter of last year, and we returned to operating income for the quarter compared to an operating loss in the prior year period. Gross profit margins improved to 26.6% from 24.8%, reflecting cost reductions and improved operating efficiencies in our operations.”

Daniel K. Frierson, Chairman and Chief Executive Officer
8:13 AM ET 8-K
Financial Results Forum Markets Inc FRMM

Forum Markets Financial Results

Forum Markets reported Q3 2026 revenue of $2.0 million and net income of $7.9 million, which included a $13.9 million non-cash gain from digital asset fair value changes. The company highlighted the formation of its Forum Edge AI joint venture and the acquisition of two additional commercial aircraft engines during the quarter.

Term
Q3 2026

“Over the past three months, we established our AI infrastructure platform through our Forum Edge AI joint venture and made it the primary focus of our capital and our growth. We have established the foundation for what we believe can become a substantial AI infrastructure business.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets

“The midterm elections significantly disrupted an already tightening AI compute market, accelerating rising costs for equipment, compute and financing. These conditions increase the value of data center capacity that is already permitted, powered and built, which is exactly what Forum has.”

McAndrew Rudisill, chairman and chief executive officer of Forum Markets
8:11 AM ET 10-Q
Financial Results Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Q3 2026 Results: Net Loss of $6.68M, Loss Narrows

Lucid Diagnostics reported a net loss of $6.7 million for the quarter ended September 30, 2026, an improvement from the $10.4 million loss in the prior year period. Total revenue remained flat year-over-year at $1.2 million, while the company significantly reduced its total liabilities from $29.5 million at year-end 2025 to $21.9 million.

Key figure
Net loss $6.68M
8:11 AM ET 8-K
Financial Results Theriva Biologics, Inc. TOVX

Theriva Biologics Financial Results

Theriva Biologics reported third quarter 2026 financial results, highlighting a cash position of $8.5 million and a runway into Q1 2027. The company also noted the completion of the sale of its SYN-004 portfolio to Biossil Labs for $350,000 upfront and up to $91 million in milestones.

“We are pleased with the clinical progress achieved this quarter. Patient enrollment and dosing in the VIRAGE2 trial is progressing well, and we anticipate completing enrollment by the end of the fourth quarter of this year.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics

“The recently signed asset sale agreement for SYN-004 (ribaxamase) and the related portfolio of antibiotic-degrading enzymes to Biossil Labs Inc. demonstrates our commitment to deriving value from our legacy microbiome programs while continuing to focus on the development of our lead program VCN-01.”

Steven A. Shallcross, Chief Executive Officer of Theriva Biologics
8:10 AM ET 8-K
Financial Results enCore Energy Corp. EU

enCore Energy Financial Results

enCore Energy reported Q3 2026 revenue of $16.7 million, an 88% increase year-over-year driven by higher uranium delivery volumes and stronger realized prices. The company reported a net loss of $33.9 million for the quarter as it focused on wellfield development at Alta Mesa and Upper Spring Creek while implementing cost-reduction measures.

Term
Q3 2026

“2026 has been a challenging year for enCore, and we have responded by reducing costs and focusing our capital where it matters most. We optimized operations to align spending with permitting timelines, while continuing to build the wellfields and infrastructure that underpin our next phase of extraction.”

Rich Little, Chief Executive Officer
8:09 AM ET 10-Q
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Q3 2026 Results: Net Loss of $29.9M, Loss Widens

Aktis Oncology reported a net loss of $72.4 million for the nine months ended September 30, 2026, compared to $48.6 million in the prior year, driven by increased R&D and G&A expenses. The company significantly strengthened its balance sheet during the period through an initial public offering and the conversion of preferred stock, ending the quarter with $492.9 million in cash and marketable securities.

Key figure
Net loss $29.9M
8:08 AM ET 8-K
Financial Results Avalyn Pharma Inc. AVLN

Avalyn Pharma Financial Results

Avalyn Pharma reported financial results for the third quarter of 2026, ending the period with $386.6 million in cash and a runway projected into 2029. The company highlighted clinical progress, including the initiation of a Phase 1 study for its AP03 combination therapy and upcoming Phase 2 data readouts for AP01 and AP02 expected in 2027.

Term
Q3 2026

“As we approach year end, I’m proud of the progress we’ve made across our portfolio and the strong foundation we’ve built for what we expect to be a transformational 2027, with data anticipated across all three of our programs.”

Lyn Baranowski, Chief Executive Officer of Avalyn

“We remain confident in the potential of inhaled therapies to transform the standard of care for pulmonary fibrosis by delivering effective, well-tolerated treatments both as monotherapies and in combination.”

Lyn Baranowski, Chief Executive Officer of Avalyn
8:08 AM ET 8-K
Financial Results MeiraGTx Holdings plc MGTX

MeiraGTx Holdings Financial Results

MeiraGTx reported third quarter 2026 financial results and provided a regulatory update for its lead candidate bota-vec, with an MAA submission to the EMA expected in December 2026 and a BLA submission to the FDA in Q1 2027. The company is preparing for a potential commercial launch of bota-vec for XLRP in late 2027 while advancing its Phase 2 AQUAx2 study for radiation-induced xerostomia.

“We are pleased to report that we have now completed much of the work towards submission of full global regulatory filings with the EMA and FDA for bota-vec for the treatment of XLRP. The MAA dossier is complete and awaiting submission and the BLA is expected to follow early next year.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx

“We are actively preparing for our pivotal Phase 2 AQUAx2 12-month data readout for the treatment of radiation-induced xerostomia in mid-2027. As we progress these two lead programs through filing for potential approval and commercialization, we are also advancing several programs towards IND.”

Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx
8:07 AM ET 10-Q
Financial Results Liqtech International Inc LIQT

Liqtech International Q3 2026 Results: Net Loss of $1.84M, Loss Widens

LiqTech International reported revenue of $12.9 million for the nine months ended September 30, 2026, a slight decrease from $13.4 million in the prior year period. The company significantly strengthened its balance sheet, increasing cash to $13.9 million and total stockholders' equity to $24.3 million, primarily through the issuance of common stock and the settlement of notes payable.

Key figure
Net loss $1.84M
8:06 AM ET 10-Q
Financial Results Creatd, Inc. CRTD

Creatd Q3 2026 Results: Net Loss of $2.77M, Loss Widens

Creatd, Inc. reported a significant increase in net loss for the nine months ended September 30, 2026, reaching $20.2 million compared to $5.1 million in the prior year, primarily driven by a surge in stock-based compensation and general administrative expenses. Net revenue declined by approximately 27% year-over-year to $603,722, while the company's total stockholders' equity decreased to $7.97 million.

Key figure
Net loss $2.77M
8:05 AM ET 8-K
Financial Results Lucid Diagnostics Inc. LUCD

Lucid Diagnostics Financial Results

Lucid Diagnostics reported third quarter 2026 financial results, highlighting the commencement of Medicare reimbursement for its EsoGuard Esophageal DNA Test at a rate of $1,938.01 per test. The company performed 2,871 tests during the quarter and reported record monthly test volume in October following the Medicare coverage milestone.

“Medicare is now paying for EsoGuard. For the first time, Medicare beneficiaries nationwide have fully reimbursed access to this groundbreaking test. This breakthrough represents a seminal moment in our mission to end the scourge of esophageal cancer and marks the start of a new phase for Lucid focused on commercial acceleration and revenue growth.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer

“Our pursuit of EsoGuard’s enormous clinical and commercial opportunity is now substantially less constrained by external factors. Lucid’s near-term growth now depends almost entirely on our team’s commercial and operational execution. Just a few weeks into this new chapter, our team delivered record monthly test volume in October and is approaching this opportunity with the urgency and determination it deserves. We are laser-focused on expanding access to EsoGuard for Medicare beneficiaries and translating this early momentum into revenue growth. What has been a marathon is now a sprint.”

Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer
8:05 AM ET 8-K
Financial Results Aktis Oncology, Inc. AKTS

Aktis Oncology Financial Results

Aktis Oncology reported financial results for the third quarter of 2026, highlighting the initiation of its third Phase 1b clinical trial (BActinium-2) for AKY-2519. The company also operationalized its in-house GMP manufacturing facility in Boston and remains on track to present preliminary clinical data for its lead programs in 2027.

Term
Q3 2026

“Aktis is on a trajectory to redefine radiopharmaceuticals as a major pillar of cancer treatment by expanding the modality to more targets, broader indications, and larger patient populations. In the third quarter, we continued to make tremendous progress operationalizing this vision.”

Matthew Roden, Ph.D., President and Chief Executive Officer

“With the initiation of the BActinium-2 trial of AKY-2519, we now have three clinical trials underway in the U.S. across two novel targets, Nectin-4 and B7-H3, which are both implicated in a range of solid tumor types. We also opened the first backfill cohorts in our ongoing NECTINIUM-2 and BActinium-1 trials to further characterize safety and preliminary antitumor activity at the selected doses, while dose escalation continues in both studies.”

Matthew Roden, Ph.D., President and Chief Executive Officer
8:05 AM ET 10-Q
Financial Results Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Q3 2026 Results: Net Loss of $41.9M, Loss Widens

Kyverna Therapeutics reported a net loss of $119.99 million for the nine months ended September 30, 2026, compared to $123.50 million in the prior year period. The company's cash and marketable securities position decreased to $170.57 million as of September 30, 2026, down from $279.25 million at the end of 2025, primarily due to ongoing research and development expenses.

Key figure
Net loss $41.9M
8:04 AM ET 8-K
Financial Results Cohen & Co Inc. COHN

Cohen & Co Financial Results

Cohen & Co Inc. reported third quarter 2026 financial results, generating $32.4 million in total revenue and $6.9 million in enterprise net income. The company's capital markets division underwrote six SPAC IPOs during the quarter, though results were impacted by $17 million in mark-to-market adjustments. Additionally, the board declared a quarterly dividend of $0.25 per share and appointed Daniel G. Cohen as CEO.

Term
3 years

“We are encouraged by the continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets (“CCM”), and in our gestation repo business. During the third quarter, CCM underwrote six SPAC IPOs and one closed-end fund, raising $1.8 billion for clients, and advised on and raised capital for eight de-SPAC transactions, exemplifying its status as a leading SPAC advisor on Wall Street.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer

“While third quarter results were unfavorably impacted by more than $17 million of mark-to-market adjustments in our investment banking and new issue revenue line, in large part due to the environment in our businesses, we still generated $6.9 million of enterprise net income and $648,000 of adjusted pre-tax income.”

Daniel G. Cohen, Executive Chairman and Chief Executive Officer
8:03 AM ET 10-Q
Financial Results Accelerant Holdings ARX

Accelerant Holdings Q3 2026 Results: Net Loss of $9.2M, Loss Narrows

Accelerant Holdings reported a net income of $66.7 million for the nine months ended September 30, 2026, a significant recovery from a net loss of $1,346.1 million in the prior year period, which was heavily impacted by a $1.38 billion non-cash profits interest distribution expense. Total revenues grew to $908.8 million for the nine-month period, driven by increases in direct commission income and net earned premiums.

Key figure
Net loss $9.2M
8:03 AM ET 10-Q
Financial Results Patriot National Bancorp Inc PNBK

Patriot National Bancorp Q3 2026 Results: Turns Profitable, Net Income $1.2M

Patriot National Bancorp reported a net income of $1.2 million for the third quarter of 2026, a significant improvement from a $2.7 million loss in the prior year period. Total assets grew to $1.5 billion as of September 30, 2026, driven by a substantial increase in loans receivable and deposits, though the company recorded a comprehensive loss of $17.7 million for the first nine months of 2026 due to unrealized losses on investment securities.

Key figure
Net income $1.2M
8:02 AM ET 8-K
Financial Results Kyverna Therapeutics, Inc. KYTX

Kyverna Therapeutics Financial Results

Kyverna Therapeutics reported Q3 2026 financial results and announced the completion of its rolling BLA submission to the FDA for miv-cel in Stiff Person Syndrome (SPS). The company ended the quarter with $312.4 million in cash and equivalents, which it expects will fund operations into 2028 as it prepares for a potential commercial launch in 2027.

Term
Q3 2026

“Kyverna is very proud to submit the first BLA for a CAR T-cell therapy in autoimmune disease, paving the way for a potential new standard of care with a single dose, designed to reset the immune system and free patients from lifelong disease and chronic immunotherapies.”

Warner Biddle, Chief Executive Officer of Kyverna
8:01 AM ET 8-K
Financial Results Btcs Inc. BTCS

Btcs Financial Results

BTCS Inc. reported record Q3 2026 financial results, highlighted by a 67% sequential revenue increase to $4.1 million and record gross profit of $3.5 million. The company surpassed its full-year gross profit target of $6 million in just nine months, driven primarily by the expansion of its Imperium liquidity pool positions to approximately $41 million.

Term
Q3 2026

“The third quarter was a breakout quarter for BTCS and Imperium. BTCS delivered a record $3.5 million in gross profit at an 86% gross margin, surpassing our full-year gross profit target of $6 million with a full quarter remaining in 2026. That performance was driven by Imperium, where we grew our paired liquidity pool positions from approximately $8 million to approximately $41 million and expanded into a multi-chain strategy with the integration of Base. Looking to the fourth quarter, we intend to keep scaling Imperium, and we expect it to remain the leading driver of our business.”

Charles Allen, Chief Executive Officer
8:01 AM ET 8-K
Financial Results Monopar Therapeutics MNPR

Monopar Therapeutics Financial Results

Monopar Therapeutics reported third quarter 2026 financial results, including a net loss of $6.2 million and a cash position of $129.4 million. The company highlighted progress on its rolling NDA submission for ALXN1840 in Wilson disease, which it expects to complete within the next several weeks.

8:01 AM ET 8-K
Financial Results Grace Therapeutics, Inc. GRCE

Grace Therapeutics Financial Results

Grace Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $2.1 million. The company is currently focused on resubmitting its New Drug Application (NDA) for GTx-104 after addressing CMC and non-clinical items identified by the FDA. Management noted that a recent $10 million financing has extended the company's cash runway through the end of 2028.

“With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.”

Prashant Kohli, Chief Executive Officer

“The financing concluded in August extends our expected cash runway through the end of calendar 2028, and positions us well as we work toward NDA resubmission.”

Prashant Kohli, Chief Executive Officer
8:01 AM ET 10-Q
Financial Results Monopar Therapeutics MNPR

Monopar Therapeutics Q3 2026 Results: Net Loss of $6.2M, Loss Widens

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on radiopharmaceuticals and copper-chelating therapies like ALXN1840. For the nine months ended September 30, 2026, the company reported 6,776,773 shares of common stock outstanding and continues to incur significant losses as it prepares a rolling NDA submission for ALXN1840.

Key figure
Net loss $6.2M
8:01 AM ET 10-Q
Financial Results Vivani Medical, Inc. VANI

Vivani Medical Q3 2026 Results: Net Loss of $7.25M, Loss Widens

Vivani Medical, Inc. is a clinical-stage company with a cash balance of $14.6 million as of September 30, 2026, down from $16.2 million at year-end 2025. The company remains pre-revenue, focusing on the development of product candidates like NPM-139 and NPM-133, and reported a total liability of $22.1 million primarily driven by lease obligations.

Key figure
Net loss $7.25M
8:01 AM ET 10-Q
Financial Results Artelo Biosciences, Inc. ARTL

Artelo Biosciences Q3 2026 Results: Net Loss of $1.77M, Loss Narrows

Artelo Biosciences reported a net loss of $7.15 million for the nine months ended September 30, 2026, compared to $8.71 million in the prior year period. The company strengthened its balance sheet through equity financing, ending the quarter with $4.44 million in cash and cash equivalents, up from $0.6 million at the start of the year.

Key figure
Net loss $1.77M
8:01 AM ET 10-Q
Financial Results Imunon, Inc. IMNN

Imunon Q3 2026 Results: Net Loss of $3.75M, Loss Widens

Imunon, Inc. reported a net loss of $10.8 million for the nine months ended September 30, 2026, compared to $10.3 million in the prior year period. The company's cash position decreased to $4.0 million from $8.8 million at year-end 2025, while total liabilities increased significantly due to the issuance of new notes payable.

Key figure
Net loss $3.75M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.